Axil Capital
Axil Capital is a venture capital firm specializing in biomedical and healthcare technology investments. They focus on supporting the growth of early-stage ventures and leveraging their global network to create synergies between the Japanese and global biotech ecosystems. Their investments span the full spectrum of the life science industry, from seed to crossover rounds.
📥 Buy Full VC Dataset
Offices: Tokyo (Japan)
Investment Stages: Series A, Series B
Markets: Biopharmaceuticals, Platform technologies, Medical devices, Digital health, Healthcare services, Artificial Intelligence (AI), Pharmaceutical, Robotics
Founded Year: 2017
Investor Type: Venture Capital
Portfolio Companies: LinqMed, Y4, MabGenesis, Pulmotect, CynosBio (formerly Hirosaki LI), Techsomed, Elixiron, GEXVal, FRAXA, Cranebio, Luca Science, Jolly Good, United Immunity, Perseus Proteomics, Allgenesis, Abrax Japan
Website: https://www.axilcapital.com/
Team Page: https://www.axilcapital.com/team-en
Portfolio Link: https://www.axilcapital.com/portfolio-en
LinkedIn: https://www.linkedin.com/company/axil-capital-partners
Crunchbase: https://www.crunchbase.com/organization/axil-capital
Pitchbook: https://pitchbook.com/profiles/investor/277480-72
Comments
No comments yet. Be the first to comment!